AE Wealth Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$71.6M Buy
329,432
+35,412
+12% +$7.86M 0.39% 62
2025
Q4
$67.2M Buy
294,020
+7,696
+3% +$1.75M 0.39% 63
2025
Q3
$66.3M Buy
286,324
+18,651
+7% +$3.8M 0.42% 54
2025
Q2
$49.7M Buy
267,673
+17,167
+7% +$3.19M 0.36% 66
2025
Q1
$52.5M Buy
250,506
+6,786
+3% +$1.32M 0.44% 53
2024
Q4
$43.3M Buy
243,720
+17,791
+8% +$3.27M 0.37% 63
2024
Q3
$44.6M Sell
225,929
-29,742
-12% -$5.55M 0.4% 55
2024
Q2
$43.9M Buy
255,671
+53,590
+27% +$8.88M 0.44% 52
2024
Q1
$36.8M Sell
202,081
-129,442
-39% -$22.3M 0.42% 57
2023
Q4
$54.5M Buy
331,523
+4,532
+1% +$661K 0.28% 72
2023
Q3
$48.7M Buy
326,991
+19,986
+7% +$2.93M 0.29% 64
2023
Q2
$41.4M Sell
307,005
-7,704
-2% -$1.13M 0.25% 76
2023
Q1
$50.2M Sell
314,709
-2,634
-0.8% -$403K 0.32% 52
2022
Q4
$51.3M Buy
317,343
+12,699
+4% +$1.95M 0.37% 43
2022
Q3
$40.9M Buy
304,644
+42,675
+16% +$6.12M 0.32% 59
2022
Q2
$40.1M Sell
261,969
-17,757
-6% -$2.71M 0.32% 68
2022
Q1
$45.3M Sell
279,726
-5,841
-2% -$848K 0.31% 64
2021
Q4
$38.7M Buy
285,567
+41,265
+17% +$4.87M 0.27% 78
2021
Q3
$26.4M Buy
244,302
+7,506
+3% +$858K 0.22% 105
2021
Q2
$26.7M Buy
236,796
+27,943
+13% +$3.15M 0.23% 103
2021
Q1
$22.6M Buy
208,853
+10,379
+5% +$1.11M 0.23% 102
2020
Q4
$21.3M Buy
198,474
+14,258
+8% +$1.37M 0.24% 97
2020
Q3
$16.1M Sell
184,216
-23,596
-11% -$2.22M 0.23% 100
2020
Q2
$20.4M Buy
207,812
+59,028
+40% +$5.2M 0.32% 71
2020
Q1
$11.3M Buy
148,784
+12,324
+9% +$1.05M 0.26% 78
2019
Q4
$12.1M Buy
136,460
+31,730
+30% +$2.63M 0.26% 79
2019
Q3
$7.93M Buy
104,730
+16,163
+18% +$1.11M 0.23% 83
2019
Q2
$6.44M Buy
88,567
+50,072
+130% +$3.94M 0.19% 94
2019
Q1
$3.1M Buy
38,495
+5,905
+18% +$483K 0.22% 94
2018
Q4
$3M Sell
32,590
-6,501
-17% -$572K 0.51% 49
2018
Q3
$3.7M Buy
39,091
+9,047
+30% +$858K 0.2% 86
2018
Q2
$2.78M Buy
30,044
+7,592
+34% +$741K 0.19% 83
2018
Q1
$2.13M Sell
22,452
-2,066
-8% -$227K 0.16% 91
2017
Q4
$2.37M Sell
24,518
-12,396
-34% -$1.17M 0.21% 80
2017
Q3
$3.28M Sell
36,914
-8,638
-19% -$658K 0.3% 57
2017
Q2
$3.3M Buy
45,552
+4,466
+11% +$300K 0.39% 52
2017
Q1
$2.68M Buy
41,086
+13,334
+48% +$838K 0.5% 41
2016
Q4
$1.74M Buy
+27,752
New +$1.69M 0.7% 29

Other funds holding ABBV

AE Wealth Management's ABBV Position: Q1 2026 in Review

AE Wealth Management increased its AbbVie (ABBV) stake by 12% in Q1 2026, buying an estimated $7.86M and bringing the position to 329,432 shares worth $71.6M. The position accounts for 0.39% of the portfolio, ranked #62.

AE Wealth Management first reported a position in ABBV in Q4 2016 and has held it in 38 quarters since. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • AE Wealth Management held 329,432 shares of AbbVie worth $71.6M as of Q1 2026.
  • AE Wealth Management bought 35,412 AbbVie shares in Q1 2026, an estimated $7.86M.
  • AbbVie made up 0.39% of AE Wealth Management's portfolio in Q1 2026, its #62 holding.
  • AE Wealth Management first reported a position in AbbVie in Q4 2016 and has held it in 38 quarters since.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on AE Wealth Management's 13F filing for Q1 2026, filed 13 May 2026.